<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="428dc1f9-b931-42be-9ba0-d6423fa43935"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use ISTURISA<sup>Â®</sup> safely and effectively. See full prescribing information for ISTURISA. <br/>
      <br/> ISTURISA (osilodrostat) tablets, for oral use <br/> Initial U.S. Approval: 2020</title>
   <effectiveTime value="20250425"/>
   <setId root="f3a5ec24-63c3-4d83-b1c0-6c550fbe7ae2"/>
   <versionNumber value="7"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="181699406" root="1.3.6.1.4.1.519.1"/>
            <name>Recordati Rare Diseases, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="488152505" root="1.3.6.1.4.1.519.1"/>
                  <name>Novartis Pharma Stein  AG</name>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="376ffaa7-d84f-4920-823a-a109029c5856"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250425"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="55292-330" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Isturisa</name>
                        <formCode code="C42897" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Osilodrostat</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="1" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Y6581YAW9V" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OSILODROSTAT PHOSPHATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="5YL4IQ1078" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>OSILODROSTAT</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4R4HFI6D95" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 4000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="55292-330-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TYPE 0: NOT A COMBINATION PRODUCT" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20251103"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="55292-330-20" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TYPE 0: NOT A COMBINATION PRODUCT" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20251103"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA212801" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20200331"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW" xsi:type="CE">
                              <originalText>PALE YELLOW</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText>ROUND, BICONVEX, BEVELED EDGE</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="6" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">1</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="55292-331" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Isturisa</name>
                        <formCode code="C42897" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Osilodrostat</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="5" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Y6581YAW9V" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OSILODROSTAT PHOSPHATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="5YL4IQ1078" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>OSILODROSTAT</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4R4HFI6D95" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 4000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="55292-331-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TYPE 0: NOT A COMBINATION PRODUCT" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20251103"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="55292-331-20" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TYPE 0: NOT A COMBINATION PRODUCT" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20251103"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA212801" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20200331"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText>ROUND, BICONVEX, BEVELED EDGE</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">5</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="55292-320" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Isturisa</name>
                        <formCode code="C42897" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>osilodrostat</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="1" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Y6581YAW9V" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OSILODROSTAT PHOSPHATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="5YL4IQ1078" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>OSILODROSTAT</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4R4HFI6D95" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 4000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="55292-320-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TYPE 0: NOT A COMBINATION PRODUCT" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20200331"/>
                                    <high value="20291231"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="55292-320-20" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TYPE 0: NOT A COMBINATION PRODUCT" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20200331"/>
                                    <high value="20291231"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA212801" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20200331"/>
                              <high value="20291231"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW" xsi:type="CE">
                              <originalText>PALE YELLOW</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText>ROUND, BICONVEX, BEVELED EDGE</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="6" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">Y1;NVR</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="55292-321" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Isturisa</name>
                        <formCode code="C42897" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>OSILODROSTAT</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="5" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Y6581YAW9V" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OSILODROSTAT PHOSPHATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="5YL4IQ1078" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>OSILODROSTAT</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4R4HFI6D95" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 4000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="55292-321-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TYPE 0: NOT A COMBINATION PRODUCT" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20200331"/>
                                    <high value="20291231"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="55292-321-20" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TYPE 0: NOT A COMBINATION PRODUCT" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20200331"/>
                                    <high value="20291231"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA212801" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20200331"/>
                              <high value="20291231"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText>ROUND, BICONVEX, BEVELED EDGE</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">Y2;NVR</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="55292-322" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Isturisa</name>
                        <formCode code="C42897" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>OSILODROSTAT</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="10" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Y6581YAW9V" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OSILODROSTAT PHOSPHATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="5YL4IQ1078" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>OSILODROSTAT</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MANNITOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4R4HFI6D95" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 4000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="60" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="55292-322-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TYPE 0: NOT A COMBINATION PRODUCT" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20200331"/>
                                    <high value="20230403"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="20" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="55292-322-20" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TYPE 0: NOT A COMBINATION PRODUCT" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20200331"/>
                                    <high value="20230403"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA212801" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20200331"/>
                              <high value="20230403"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48332" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BROWN" xsi:type="CE">
                              <originalText>PALE ORANGE BROWN</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText>ROUND, BICONVEX, BEVELED EDGE</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">Y3;NVR</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="faad5835-6ca1-487d-a22d-ddbd0653a196"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250425"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="50%" align="left" valign="middle"/>
                           <col width="50%" align="right" valign="middle"/>
                           <tbody>
                              <tr>
                                 <td>Indications and Usage (<linkHtml href="#S1">1</linkHtml>)</td>
                                 <td>04/2025</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="fcb32245-120e-4987-a851-595480b226dc"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>
                     <content styleCode="xmChange">ISTURISA is indicated for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250425"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>ISTURISA is a cortisol synthesis inhibitor indicated for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="6d239726-e501-41fd-8965-ba7f735ec9a1"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250425"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Correct hypokalemia and hypomagnesemia, and obtain baseline electrocardiogram prior to starting ISTURISA (<linkHtml href="#S2.1">2.1</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>, <linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item>Initiate dosage at 2 mg orally twice daily, with or without food (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                           <item>Titrate dosage by 1 to 2 mg twice daily, no more frequently than every 2 weeks based on rate of cortisol changes, individual tolerability and improvement in signs and symptoms (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                           <item>Maximum recommended dosage is 30 mg twice daily (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                           <item>See Full Prescribing Information for complete titration, laboratory, and dosage modification recommendations (<linkHtml href="#S2.1">2.1</linkHtml>, <linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S2.3">2.3</linkHtml>)</item>
                           <item>Patients with Hepatic Impairment: 									<list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="italics">Child-Pugh B:</content> Recommended starting dose is 1 mg twice daily (<linkHtml href="#S2.5">2.5</linkHtml>, <linkHtml href="#S8.7">8.7</linkHtml>
                                    <content styleCode="italics">)</content>
                                 </item>
                                 <item>
                                    <content styleCode="italics">Child-Pugh C</content>: Recommended starting dose is 1 mg once daily in the evening (<linkHtml href="#S2.5">2.5</linkHtml>, <linkHtml href="#S8.7">8.7</linkHtml>)</item>
                              </list>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="f101ef22-bd0f-4647-80eb-b9d62995658f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	Laboratory Testing Prior to ISTURISA Initiation</title>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Correct hypokalemia and hypomagnesemia prior to starting ISTURISA <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2</linkHtml>, <linkHtml href="#S5.3">5.3)</linkHtml>].</content>
                           </item>
                           <item>Obtain baseline electrocardiogram (ECG)<content styleCode="italics">.</content> Repeat ECG within one week after treatment initiation, and as clinically indicated thereafter <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="68ecf74d-16a0-42d8-91e6-f2d718de85b6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	Recommended Dosage, Titration, and Monitoring</title>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Initiate dosing at 2 mg orally twice daily, with or without food.</item>
                           <item>Initially, titrate the dosage by 1 to 2 mg twice daily, no more frequently than every 2 weeks based on the rate of cortisol changes, individual tolerability and improvement in signs and symptoms of Cushing's syndrome. If a patient tolerates ISTURISA dosage of 10 mg twice daily and continues to have elevated 24-hour urine free cortisol (UFC) levels above upper normal limit, the dosage can be titrated further by 5 mg twice daily every 2 weeks. Monitor cortisol levels from at least two 24-hour urine free cortisol collections every 1-2 weeks until adequate clinical response is maintained.</item>
                           <item>The maintenance dosage of ISTURISA is individualized and determined by titration based on cortisol levels and patient's signs and symptoms.</item>
                           <item>The maintenance dosage varied between 2 mg and 7 mg twice daily in clinical trials. The maximum recommended maintenance dosage of ISTURISA is 30 mg twice daily.</item>
                           <item>Once the maintenance dosage is achieved, monitor cortisol levels at least every 1-2 months or as indicated.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="4014d854-28de-4478-9424-4dd9364329a2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3	Dosage Interruptions and Modifications</title>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Decrease or temporarily discontinue ISTURISA if urine free cortisol levels fall below the target range, there is a rapid decrease in cortisol levels, and/or patients report symptoms of hypocortisolism. If necessary, glucocorticoid replacement therapy should be initiated.</item>
                           <item>Stop ISTURISA and administer exogenous glucocorticoid replacement therapy if serum or plasma cortisol levels are below target range and patients have symptoms of adrenal insufficiency <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].</content>
                           </item>
                           <item>If treatment is interrupted, re-initiate ISTURISA at a lower dose when cortisol levels are within target ranges and patient symptoms have been resolved.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="01544c32-88d9-4ed4-bad6-2c10af0b9f4b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4	Recommended Dosage and Monitoring in Patients with Renal Impairment</title>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>No dose adjustment is required for patients with renal impairment. Use caution in interpreting urine free cortisol levels in patients with moderate to severe renal impairment, due to reduced urine free cortisol excretion <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.5">
                     <id root="659b15c0-f874-4683-bc2c-365333aeaeff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5	Recommended Dosage and Monitoring in Patients with Hepatic Impairment</title>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>For patients with moderate hepatic impairment (Child-Pugh B), the recommended starting dose is 1 mg twice daily. For patients with severe hepatic impairment (Child-Pugh C), the recommended starting dose is 1 mg once daily in the evening. </item>
                           <item>No dose adjustment is required for patients with mild hepatic impairment (Child-Pugh A).</item>
                           <item>More frequent monitoring of adrenal function may be required during dose titration in all patients with hepatic impairment <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.6">
                     <id root="f5ca86c8-aea5-4f8e-a735-83b1f9df40f4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6	Missed Dose</title>
                     <text>
                        <paragraph>If a dose of ISTURISA is missed, the patient should take their next dose at the regularly scheduled time.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="d62413c9-2c56-4cf5-b7e9-110027a3d17a"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>ISTURISA is available as:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>1 mg tablets: Pale yellow, unscored, round, biconvex with beveled edge tablet, debossed "1" on one side.</item>
                     <item>5 mg tablets: Yellow, unscored, round, biconvex with beveled edge tablet, debossed "5" on one side.</item>
                  </list>
               </text>
               <effectiveTime value="20250425"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Tablets:</content> 1 mg and 5 mg (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="0c4f1b6b-8c0b-41af-bfe2-c55a1e3598d9"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20250425"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="f2b32486-3bff-4f0f-96d4-19f2513e950c"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250425"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="italics">Hypocortisolism</content>: Monitor patients closely for hypocortisolism and potentially life-threatening adrenal insufficiency. Dosage reduction or interruption may be necessary (<linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">QTc Prolongation</content>: Perform electrocardiogram in all patients Use with caution in patients with risk factors for QTc prolongation (<linkHtml href="#S5.2">5.2</linkHtml>) </item>
                           <item>
                              <content styleCode="italics">Elevations in Adrenal Hormone Precursors and Androgens:</content> Monitor for hypokalemia, worsening of hypertension, edema, and hirsutism (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="79310213-2664-4755-922f-a18e28901623"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Hypocortisolism</title>
                     <text>
                        <paragraph>ISTURISA lowers cortisol levels and can lead to hypocortisolism and sometimes life-threatening adrenal insufficiency. Lowering of cortisol can cause nausea, vomiting, fatigue, abdominal pain, loss of appetite, dizziness. Significant lowering of serum cortisol may result in hypotension, abnormal electrolyte levels, and hypoglycemia <content styleCode="italics">[see <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>]</content>. </paragraph>
                        <paragraph>Hypocortisolism can occur at any time during ISTURISA treatment. Evaluate patients for precipitating causes of hypocortisolism (infection, physical stress, etc.). Monitor 24-hour urine free cortisol, serum or plasma cortisol, and patient's signs and symptoms periodically during ISTURISA treatment.</paragraph>
                        <paragraph>Decrease or temporarily discontinue ISTURISA if urine free cortisol levels fall below the target range, there is a rapid decrease in cortisol levels, and/or patients report symptoms of hypocortisolism. Stop ISTURISA and administer exogenous glucocorticoid replacement therapy if serum or plasma cortisol levels are below target range and patients have symptoms of adrenal insufficiency. Re-initiate ISTURISA at a lower dose when urine free cortisol, serum or plasma cortisol levels are within target range, and/or patient symptoms have resolved. After ISTURISA discontinuation, cortisol suppression may persist beyond the 4 hour half-life of ISTURISA.</paragraph>
                        <paragraph>Educate patients on the symptoms associated with hypocortisolism and advise them to contact a healthcare provider if they occur.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="29fc3bcc-6545-4950-a63f-3a09890ad00a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	QTc Prolongation</title>
                     <text>
                        <paragraph>ISTURISA is associated with a dose-dependent QT interval prolongation (maximum mean estimated QTcF increase of up to 5.3 ms at 30 mg), which may cause cardiac arrhythmias <content styleCode="italics">[see <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>
                           </content>, <content styleCode="italics">
                              <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>
                           </content>].</paragraph>
                        <paragraph>Perform an ECG to obtain a baseline QTc interval measurement prior to initiating therapy with ISTURISA and monitor for an effect on the QTc interval thereafter. Correct hypokalemia and/or hypomagnesemia prior to ISTURISA initiation and monitor periodically during treatment with ISTURISA. Correct electrolyte abnormalities if indicated. Consider temporary discontinuation of ISTURISA in the case of an increase in QTc interval &gt; 480 ms.</paragraph>
                        <paragraph>Use caution in patients with risk factors for QT prolongation, (such as congenital long QT syndrome, congestive heart failure, bradyarrhythmias, uncorrected electrolyte abnormalities, and concomitant medications known to prolong the QT interval) and consider more frequent ECG monitoring.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="b14d22b3-2ab1-406b-8fc8-2c32078dc68b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Elevations in Adrenal Hormone Precursors and Androgens</title>
                     <text>
                        <paragraph>ISTURISA blocks cortisol synthesis and may increase circulating levels of cortisol and aldosterone precursors (11-deoxy cortisol and 11-deoxycorticosterone) and androgens.</paragraph>
                        <paragraph>Elevated 11-deoxycorticosterone levels may activate mineralocorticoid receptors and cause hypokalemia, edema and hypertension <content styleCode="italics">[see <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>]</content>. Hypokalemia should be corrected prior to initiating ISTURISA. Monitor patients treated with ISTURISA for hypokalemia, worsening of hypertension and edema. ISTURISA-induced hypokalemia should be treated with intravenous or oral potassium supplementation based on event severity. If hypokalemia persists despite potassium supplementation, consider adding mineralocorticoid antagonists. ISTURISA dose reduction or discontinuation may be necessary.</paragraph>
                        <paragraph>Accumulation of androgens may lead to hirsutism, hypertrichosis and acne (in females). Inform patients of the symptoms associated with hyperandrogenism and advise them to contact a healthcare provider if they occur.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="6bd1c291-3938-4706-9fb8-481f7a606a2d"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Clinically significant adverse reactions that appear in other sections of the labeling include:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Hypocortisolism <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>QT Prolongation <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Elevations in Adrenal Hormone Precursors and Androgens <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250425"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (incidence &gt; 20%) are adrenal insufficiency, fatigue, nausea, headache, edema (<linkHtml href="#S6">6</linkHtml>)</paragraph>
                        <br/>
                        <paragraph styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Recordati Rare Diseases Inc. at 1-888-575-8344 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="e813ba43-71ff-4406-b2d1-2f50d7015183"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>A total of 137 Cushing's disease patients were exposed to ISTURISA in the study <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>. The adverse reactions that occurred with frequency higher than 10% during the core 48-week period are shown in Table 1.</paragraph>
                        <table width="80%">
                           <caption>Table 1: Adverse Reactions With a Frequency of More Than 10% in 48-week Clinical Study in Cushing's Disease Patients</caption>
                           <col width="50%" align="left" valign="middle"/>
                           <col width="50%" align="left" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Adverse Reaction Type</th>
                                 <th styleCode="Rrule">(N = 137) <br/> %</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Adrenal insufficiency<footnote>
                                       <content styleCode="italics">Adrenal insufficiency includes glucocorticoid deficiency, adrenocortical insufficiency acute, steroid withdrawal syndrome, cortisol free urine decreased, cortisol decreased. One-third of the subjects with this event had low cortisol levels indicative of Adrenal Insufficiency. The majority of subjects had normal cortisol levels suggesting a cortisol withdrawal syndrome.</content>
                                    </footnote>
                                 </td>
                                 <td styleCode="Rrule">43.1</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Fatigue<footnote>
                                       <content styleCode="italics">Fatigue includes lethargy, asthenia</content>
                                    </footnote>
                                 </td>
                                 <td styleCode="Rrule">38.7</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Nausea</td>
                                 <td styleCode="Rrule">37.2</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Headache<footnote>
                                       <content styleCode="italics">Headache includes head discomfort.</content>
                                    </footnote>
                                 </td>
                                 <td styleCode="Rrule">30.7</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Edema<footnote>
                                       <content styleCode="italics">Edema includes edema peripheral, generalized edema, localized edema.</content>
                                    </footnote>
                                 </td>
                                 <td styleCode="Rrule">21.2</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Nasopharyngitis</td>
                                 <td styleCode="Rrule">19.7</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Vomiting</td>
                                 <td styleCode="Rrule">19</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Arthralgia</td>
                                 <td styleCode="Rrule">17.5</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Back pain</td>
                                 <td styleCode="Rrule">15.3</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Rash<footnote>
                                       <content styleCode="italics">Rash includes rash erythematous, rash generalized, rash maculopapular, rash papular.</content>
                                    </footnote>
                                 </td>
                                 <td styleCode="Rrule">15.3</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Diarrhea</td>
                                 <td styleCode="Rrule">14.6</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Blood corticotrophin increased</td>
                                 <td styleCode="Rrule">13.9</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Dizziness<footnote>
                                       <content styleCode="italics">Dizziness includes dizziness postural.</content>
                                    </footnote>
                                 </td>
                                 <td styleCode="Rrule">13.9</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Abdominal pain<footnote>
                                       <content styleCode="italics">Abdominal pain includes abdominal pain upper, abdominal discomfort</content>
                                    </footnote>
                                 </td>
                                 <td styleCode="Rrule">13.1</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Hypokalaemia<footnote>
                                       <content styleCode="italics">Hypokalaemia includes blood potassium decreased.</content>
                                    </footnote>
                                 </td>
                                 <td styleCode="Rrule">12.4</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Myalgia</td>
                                 <td styleCode="Rrule">12.4</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Decreased appetite</td>
                                 <td styleCode="Rrule">11.7</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Hormone level abnormal</td>
                                 <td styleCode="Rrule">11.7</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Hypotension<footnote>
                                       <content styleCode="italics">Hypotension includes orthostatic hypotension, blood pressure decreased, blood pressure diastolic decreased, blood pressure systolic decreased.</content>
                                    </footnote>
                                 </td>
                                 <td styleCode="Rrule">11.7</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Urinary tract infection</td>
                                 <td styleCode="Rrule">11.7</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Blood testosterone increased</td>
                                 <td styleCode="Rrule">10.9</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Pyrexia</td>
                                 <td styleCode="Rrule">10.9</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Anemia</td>
                                 <td styleCode="Rrule">10.2</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Cough</td>
                                 <td styleCode="Rrule">10.2</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">Hypertension</td>
                                 <td styleCode="Rrule">10.2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Influenza</td>
                                 <td styleCode="Rrule">10.2</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Other notable adverse reactions which occurred with a frequency less than 10% were: hirsutism (9.5%), acne (8.8%), dyspepsia (8%), insomnia (8%), anxiety (7.3%), depression (7.3%), gastroenteritis (7.3%), malaise (6.6%), tachycardia (6.6%), alopecia (5.8%), transaminases increased (4.4%), electrocardiogram QT prolongation (3.6%), and syncope (1.5%).</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                     <component>
                        <section>
                           <id root="b5a56965-3627-49f2-b335-00780e44c750"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Description of Selected Adverse Reactions</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250425"/>
                           <component>
                              <section>
                                 <id root="4dd6a82e-b4ff-4c78-bfc8-96ec66f621b2"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Gastrointestinal Disorders</content>
                                    </paragraph>
                                    <paragraph>Gastrointestinal disorders, predominantly nausea, vomiting, diarrhea and abdominal pain were reported in 69% of patients. In many cases, the episodes were of short duration (1-2 days) and the severity was mild to moderate.</paragraph>
                                 </text>
                                 <effectiveTime value="20250425"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3aa91f26-b2be-4715-81e8-ad3415c74114"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Hypocortisolism</content>
                                    </paragraph>
                                    <paragraph>Hypocortisolism was reported at a rate of 31% up to 12 weeks, and 18% from Weeks 12 to 26. The majority of cases were manageable by reducing the dose of ISTURISA and/or adding low-dose, short-term glucocorticoid therapy<content styleCode="italics">.</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250425"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="2aa70162-9ba3-4369-a006-65e149b7ddaf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Changes in Pituitary Tumor Volume</content>
                                    </paragraph>
                                    <paragraph>An increase in the pituitary corticotroph tumor volume by greater than 20% from baseline was observed in 21/137 (15%) patients, while a decrease in tumor volume by greater than 20% from baseline was observed in 24/137 (18%) patients at Week 48. Eight patients discontinued because of an increase in tumor volume. There was no correlation between tumor volume increase and increase in adrenocorticotrophic hormone (ACTH). There was no specific pattern of timing of the tumor volume increase and no relationship with the total and the last dose of ISTURISA used in the study.</paragraph>
                                 </text>
                                 <effectiveTime value="20250425"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="ee42244a-9370-4341-a940-50f315352081"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">QTc Interval Prolongation</content>
                                    </paragraph>
                                    <paragraph>Adverse reactions of QT prolongation and clinically relevant ECG findings were reported. Five (4%) patients had an event of QT prolongation, 3 (2%) patients had a QTcF increase of &gt; 60ms from baseline, and 18 (13%) had a new QTcF value of &gt; 450ms <content styleCode="italics">[see <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20250425"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="e72b8a95-9ac2-4e7e-aff2-b56a678ef942"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Accumulation of Adrenal Hormone Precursors</content>
                                    </paragraph>
                                    <paragraph>CYP11B1 inhibition by ISTURISA is associated with adrenal steroid precursor accumulation and testosterone increases <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>. The incidence of adverse reactions potentially related to accumulation of adrenal hormone precursors was 42%. Hypertension and hypokalemia were the most common adrenal hormone precursor-related adverse reactions and occurred in 14% of patients and 17% of patients, respectively; edema was reported in 7% of patients, elevated blood pressure in 15% of patients. All cases of hypokalemia responded to treatment with potassium supplementation and/or mineralocorticoid antagonist therapy (e.g., spironolactone). One patient discontinued the study because of hypokalemia. In male patients testosterone levels generally increased but remained within normal limits; all patients were asymptomatic with no values above upper limit of normal (ULN) at last available value. In female patients, mean testosterone levels increased above the normal range from baseline and reversed when treatment was interrupted. The testosterone increase was associated with mild to moderate cases of hirsutism (12%) or acne (11%) in a subset of female patients.</paragraph>
                                 </text>
                                 <effectiveTime value="20250425"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="a37fc101-a103-4dcb-9a6d-1b178067f9d8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Other Abnormal Laboratory Findings</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250425"/>
                           <component>
                              <section>
                                 <id root="1dba8662-0a41-44fc-a408-c5da37c42fa9"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Decreased Absolute Neutrophil Count</content>
                                    </paragraph>
                                    <paragraph>Of the 137 patients from the 48-week study, 18 patients had at least one measured absolute neutrophil count below the normal limit, 2 patients had an adverse reaction of neutropenia. No concomitant infections and/or fever were reported in patients with decreased absolute neutrophil count.</paragraph>
                                 </text>
                                 <effectiveTime value="20250425"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="016d27cf-aa7f-4f67-9374-beccb414a99e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Elevated Liver Function Tests </content>
                                    </paragraph>
                                    <paragraph>Liver enzyme elevations in patients treated with ISTURISA were infrequent, typically mild and reversed spontaneously or following dose adjustment. Most liver abnormal parameters occurred during the dose-titration period and no patients discontinued ISTURISA drug due to abnormal liver chemistry parameters. Five (4%) patients had ALT or AST &gt; 3 Ã ULN during the 48-week clinical study.</paragraph>
                                 </text>
                                 <effectiveTime value="20250425"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="3f16cf3f-ef2c-41d7-8762-966b0b164a30"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250425"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="italics">CYP3A4 Inhibitor:</content> Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor (<linkHtml href="#S7.1">7.1</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">CYP3A4 and CYP2B6 Inducers:</content> An increase of ISTURISA dosage may be needed if ISTURISA is used concomitantly with strong CYP3A4 and CYP2B6 inducers. A reduction in ISTURISA dosage may be needed if strong CYP3A4 and CYP2B6 inducers are discontinued while using ISTURISA (<linkHtml href="#S7.1">7.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="eebec066-1cdb-46d0-ae1b-76a6d166bfa8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1	Effect of Other Drugs on ISTURISA</title>
                     <text>
                        <paragraph>The effect of other drugs on ISTURISA can be found in Table 2.</paragraph>
                        <table width="85%">
                           <caption>Table 2: Effect of Other Drugs on ISTURISA</caption>
                           <col width="30%" align="left" valign="top"/>
                           <col width="70%" align="left" valign="bottom"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" colspan="2">CYP3A4 Inhibitors</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="italics">Clinical Impact:</content>
                                 </td>
                                 <td styleCode="Rrule">Concomitant use of ISTURISA with a strong CYP3A4 inhibitor (e.g., itraconazole, clarithromycin) may cause an increase in osilodrostat concentration and may increase the risk of ISTURISA-related adverse reactions <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Intervention</content>:</td>
                                 <td styleCode="Rrule">Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor.</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">
                                    <content styleCode="bold">CYP3A4 and CYP2B6 Inducers </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Clinical Impact:</content>
                                 </td>
                                 <td styleCode="Rrule">Concomitant use of ISTURISA with strong CYP3A4 and/or CYP2B6 inducers (e.g., carbamazepine, rifampin, phenobarbital) may cause a decrease in osilodrostat concentration and may reduce the efficacy of ISTURISA <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</td>
                              </tr>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule"/>
                                 <td styleCode="Rrule">Discontinuation of strong CYP3A4 and/or CYP2B6 inducers while using ISTURISA may cause an increase in osilodrostat concentration and may increase the risk of ISTURISA-related adverse reactions <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="italics">Intervention:</content>
                                 </td>
                                 <td styleCode="Rrule">During concomitant use of ISTURISA with strong CYP3A4 and CYP2B6 inducers, monitor cortisol concentration and patient's signs and symptoms. An increase in ISTURISA dosage may be needed.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule"/>
                                 <td styleCode="Rrule">Upon discontinuation of strong CYP3A4 and CYP2B6 inducers during ISTURISA treatment, monitor cortisol concentration and patient's signs and symptoms. A reduction in ISTURISA dosage may be needed.</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="51bf07ba-fa4b-41b8-b002-6fbb69917bfd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2	Effect of ISTURISA on Other Drugs</title>
                     <text>
                        <paragraph>ISTURISA should be used with caution when coadministered with CYP1A2 and CYP2C19 substrates with a narrow therapeutic index, such as theophylline, tizanidine, and S-mephenytoin <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="ceb25b20-12a2-41f2-95bf-9968200b53f0"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250425"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="italics">Lactation</content>: Breastfeeding is not recommended during treatment with ISTURISA and for at least one week after treatment (<linkHtml href="#S8.2">8.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="a190a29d-cffc-41c6-9558-155ac0c5580a"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250425"/>
                     <component>
                        <section>
                           <id root="7a0d1b3b-184f-4956-b82a-a6000ea95a43"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary </content>
                              </paragraph>
                              <paragraph>There are no available data on osilodrostat use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with active Cushing's Syndrome during pregnancy <content styleCode="italics">(see <linkHtml href="#CC">Clinical Considerations</linkHtml>).</content>
                              </paragraph>
                              <paragraph>No adverse developmental outcomes were observed in reproduction studies in pregnant rats and rabbits when exposed to osilodrostat during organogenesis at doses that produced maternal exposures of 7 and 0.5-times the 30 mg twice daily maximum clinical dose, by AUC. In rabbits, exposures associated with maternal toxicity at 7-times the maximum clinical dose resulted in decreased fetal viability. No adverse developmental outcomes were observed in a pre- and postnatal development study with administration of osilodrostat to pregnant rats from organogenesis through lactation at 8-times the 30 mg twice daily maximum clinical dose <content styleCode="italics">(see <linkHtml href="#Data">Data</linkHtml>).</content>
                              </paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250425"/>
                        </section>
                     </component>
                     <component>
                        <section ID="CC">
                           <id root="f684d5d4-1ddf-4af6-a89f-35afe2bb5f9a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250425"/>
                           <component>
                              <section>
                                 <id root="2852c308-44d8-446f-a075-43e71b0fa62b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Disease-Associated Maternal and/or Embryo/Fetal Risk</content>
                                    </paragraph>
                                    <paragraph>Active Cushing Syndrome during pregnancy has been associated with an increased risk of maternal and fetal morbidity and mortality (including gestational diabetes, gestational hypertension, pre-eclampsia, maternal death, miscarriage, fetal loss, and preterm birth).</paragraph>
                                 </text>
                                 <effectiveTime value="20250425"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="Data">
                           <id root="d27118d3-5cce-414a-b95d-b765186924ae"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250425"/>
                           <component>
                              <section>
                                 <id root="26164e4d-477c-4197-a9e2-0d0872938231"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Osilodrostat administered to pregnant Wistar Han rats from gestation day 6-17 at doses of 0.5, 5, 50 mg/kg did not adversely affect embryo-fetal development up to 5 mg/kg (8-times the 30mg twice daily maximum clinical dose, by AUC). Maternal toxicity, increased embryonic and fetal deaths, decreased fetal weights, and malformations occurred at 50 mg/kg (118-times the maximum clinical dose, by AUC).</paragraph>
                                    <paragraph>Osilodrostat administered to pregnant New Zealand rabbits from gestation day 7-20 at doses of 3, 10, and 30 mg/kg did not adversely affect embryo-fetal development at 3mg/kg (0.5-times the 30 mg twice daily maximum clinical dose, by AUC). Maternal toxicity, increased embryo resorption and decreased fetal viability was observed at â¥ 10mg/kg (7-times the maximum clinical dose, by AUC).</paragraph>
                                    <paragraph>Osilodrostat administered to Wistar Han rats from gestation day 6 through lactation day 20 at doses of 1, 5, and 20 mg/kg did not adversely impact behavioral, developmental, or reproductive parameters up to 5 mg/kg (~ 8 times the 30 mg twice daily maximum clinical dose, by AUC). Delayed parturition and dystocia in maternal rats and decreased pup survival were observed at 20 mg/kg (43-times the maximum clinical dose, by AUC). </paragraph>
                                 </text>
                                 <effectiveTime value="20250425"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="cee1493b-a577-4df2-a588-f00b276de841"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250425"/>
                     <component>
                        <section>
                           <id root="b65cca80-c4b6-4eab-b916-b9e4e90f4468"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no available data on the presence of osilodrostat in human or animal milk, the effects on the breastfed infant, or the effects on milk production. Because of the potential for serious adverse reactions (such as adrenal insufficiency) in the breastfed infant, advise patients that breastfeeding is not recommended during treatment with ISTURISA and for one week after the final dose.</paragraph>
                           </text>
                           <effectiveTime value="20250425"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="d52ca023-286a-4716-a880-7b0a9d216265"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of ISTURISA in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="84364852-547f-4259-9d91-3e5f2d9639b3"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of the 167 patients in clinical trials with ISTURISA, 10 (6%) were 65 years and older. There were no patients above 75 years of age. Based on the available data on the use of ISTURISA in patients older than 65 years, no dosage adjustment is required <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="b85d6140-8934-457c-89d3-36e864fd9eae"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>No dosage adjustment of ISTURISA in patients with impaired renal function is required <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. In patients with moderate to severe renal impairment, UFC levels should be interpreted with caution due to reduced UFC excretion. </paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="3a07812a-fd31-44d3-b49e-258c53c4d7c5"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7	Hepatic Impairment</title>
                     <text>
                        <paragraph>Dosage adjustment is not required in patients with mild hepatic impairment (Child-Pugh A) but is required for patients with moderately impaired hepatic function (Child-Pugh B) and for patients with severe hepatic impairment (Child-Pugh C) <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. More frequent monitoring of adrenal function may be required during dose titration in all patients with hepatic impairment. </paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="3f62ef1e-0b95-493c-8303-649d7e4e5cf9"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Overdosage may result in severe hypocortisolism. Signs and symptoms suggestive of hypocortisolism may include nausea, vomiting, fatigue, low blood pressure, abdominal pain, loss of appetite, dizziness, and syncope. </paragraph>
                  <paragraph>In case of suspected overdosage, ISTURISA should be temporarily discontinued, cortisol levels should be checked, and if necessary, corticosteroid supplementation should be initiated. Close surveillance may be necessary, including monitoring of the QT interval, blood pressure, glucose, fluid, and electrolyte until the patient's condition is stable. </paragraph>
               </text>
               <effectiveTime value="20250425"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="e7835b49-a78d-4891-9dd8-8a4f8b9bb9ce"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>ISTURISA (osilodrostat) is a cortisol synthesis inhibitor. </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>The chemical name of osilodrostat is 4-[(5<content styleCode="italics">R</content>)-6,7-Dihydro-5<content styleCode="italics">H</content>-pyrrolo[1,2-<content styleCode="italics">c</content>]imidazol-5-yl]-3-fluorobenzonitrile dihydrogen phosphate.</paragraph>
                  <paragraph>Molecular formula of osilodrostat salt (phosphate) form on anhydrous basis is: (C<sub>13</sub>H<sub>11</sub>FN<sub>3</sub>) (H<sub>2</sub>PO<sub>4</sub>). Relative molecular mass of osilodrostat phosphate salt form is 325.24 g/mol.</paragraph>
                  <paragraph>ISTURISA tablets for oral administration contains 1 mg or 5 mg of osilodrostat equivalent to 1.4 mg or 7.2 mg of osilodrostat phosphate respectively, and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, mannitol, microcrystalline cellulose, and magnesium stearate. The film coat is composed of hypromellose, titanium dioxide, ferric oxide (yellow), ferric oxide (red) (1 mg only), polyethylene glycol 4000, and talc.</paragraph>
               </text>
               <effectiveTime value="20250425"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="isturisa-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="f444677d-6ee4-42c3-9be0-4980cb281b7f"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250425"/>
               <component>
                  <section ID="S12.1">
                     <id root="6713dc50-e2c1-45ea-b4bd-ffa54a780565"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Osilodrostat is a cortisol synthesis inhibitor. It inhibits 11beta-hydroxylase (CYP11B1), the enzyme responsible for the final step of cortisol biosynthesis in the adrenal gland. In a Chinese hamster lung cell line V79-4 that overexpresses human CYP11B1, adrenodoxin and adrenodoxin reductase, osilodrostat inhibited the activity of human CYP11B1 dose-dependently with IC50 values of 2.5 Â± 0.1 nM (n = 4).</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="c7580980-9cb8-4b9e-b79b-86651e451e94"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>A dose dependent increase was observed in 11-deoxycortisol, the cortisol precursor, and ACTH levels in patients with Cushing's disease.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                     <component>
                        <section>
                           <id root="79d2e3b9-c38b-4c3c-8a8f-4341ddfd987b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cardiac Electrophysiology</content>
                              </paragraph>
                              <paragraph>A thorough QT study in 86 male and female healthy volunteers showed a maximum mean placebo-corrected QTcF interval increase of 1.73 ms [90% confidence interval (CI): 0.15, 3.31] at a 10 mg dose, and 25.38 ms (90% CI: 23.53, 27.22) at a 150 mg dose (up to 2.5 times the maximum recommended dosage) <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                              <paragraph>The predicted mean placebo-corrected QTcF change from baseline at the highest recommended dose in clinical practice (30 mg twice daily) was estimated as 5.3 ms (90% CI: 4.2, 6.5), based on an interpolation of the data from the thorough QT Study and population PK analysis <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250425"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="745b0318-c69b-4055-acad-674b8425cbb3"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20250425"/>
                     <component>
                        <section>
                           <id root="2b4ff7d6-0647-43d1-8219-9607650453cf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>Osilodrostat is absorbed with a time of maximum observed concentration (T<sub>max</sub>) of approximately 1 hour. Exposure (AUC<sub>inf</sub> and C<sub>max</sub>) slightly increases over dose-proportionally within the therapeutic dose range of 1 mg to 30 mg. </paragraph>
                           </text>
                           <effectiveTime value="20250425"/>
                           <component>
                              <section>
                                 <id root="1eb7bdff-d75f-474c-b9d8-a2666fc135d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Effect of Food</content>
                                    </paragraph>
                                    <paragraph>In a healthy volunteer study (N = 20), subjects administered with a single, 30 mg oral dose of ISTURISA film-coated tablets with a high-fat meal resulted in reduction of AUC by 11% and C<sub>max</sub> by 21%, respectively. The median T<sub>max</sub> was delayed from 1 to 2.5 hours. These changes are not considered to be clinically significant, therefore ISTURISA can be administered with or without food.</paragraph>
                                 </text>
                                 <effectiveTime value="20250425"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="21993bf4-2f34-48c5-abb3-b8cf9f0b0f9b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>The median apparent volume of distribution of osilodrostat is approximately 100 L. Protein binding is low (36.4%). The osilodrostat blood-to-plasma concentration ratio is 0.85. </paragraph>
                           </text>
                           <effectiveTime value="20250425"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="d580099b-340a-4b8c-b6b0-3cb7014f719e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The elimination half-life of osilodrostat is approximately 4 hours.</paragraph>
                              <paragraph>In an absorption, distribution, metabolism, and excretion study, the majority of the radioactivity dose of osilodrostat is eliminated in the urine (mean: 90.6% of administered dose) with only a minor amount eliminated in the feces (1.58% of dose). The low percentage of the dose eliminated in the urine as unchanged osilodrostat (5.2%) indicates that metabolism is the major clearance pathway in humans.</paragraph>
                           </text>
                           <effectiveTime value="20250425"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="a1375eb4-35a8-49af-94e8-eaf6976498c0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Metabolism</content>
                              </paragraph>
                              <paragraph>Multiple CYP enzymes (i.e., CYP3A4, CYP2B6, and CYP2D6) and UDP-glucuronosyltransferases contribute to osilodrostat metabolism and no single enzyme contributes greater than 25% to the total clearance. The metabolites are not expected to contribute to the pharmacological effect of osilodrostat.</paragraph>
                           </text>
                           <effectiveTime value="20250425"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="4ea4e602-aac2-42be-a52c-ea24ef4c4d04"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>Age and gender have no significant impact on osilodrostat exposure in adults. </paragraph>
                           </text>
                           <effectiveTime value="20250425"/>
                           <component>
                              <section>
                                 <id root="41ddfe7d-27f5-48c3-b5a5-365becba1187"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Race/Ethnicity</content>
                                    </paragraph>
                                    <paragraph>The relative bioavailability in Asian patients is approximately 20% higher compared to that of non-Asian, along with higher T<sub>max</sub> and C<sub>max</sub>, compared to other ethnicities. However, the difference is not clinically significant.</paragraph>
                                 </text>
                                 <effectiveTime value="20250425"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3ddf4170-fbf5-413a-9bd9-9801cd777e40"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>Osilodrostat exposure was similar in the three renal function groups [normal, severe, and end stage renal disease (ESRD) groups] and thus a study was not conducted in mild and moderate renal impairment groups. The results showed that the PK of osilodrostat was not influenced by varying degrees of renal impairment to any clinically significant extent <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>, <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20250425"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="353e9c8c-bcb4-4b6e-8fc2-89d4eb7bc85d"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>There was a trend of increasing AUC<sub>inf</sub> to osilodrostat in moderate and severe hepatic impaired subjects (geo-mean ratios are 1.44 and 2.66, respectively) as compared to normal subjects. Exposures (C<sub>max</sub> and AUC) of osilodrostat in the mild hepatic impairment group were similar to those in the normal group <content styleCode="italics">[see <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml>, <linkHtml href="#S8.7">Use in Specific Populations (8.7)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20250425"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2cbfc717-2f62-4853-9185-d3736e51b518"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction</content>
                              </paragraph>
                              <paragraph>In a healthy volunteer study (N = 20) using a single dose of osilodrostat (50 mg) and a probe drugs cocktail, osilodrostat showed inhibition potential on CYP1A2, CYP2C19, CYP2D6, and CYP3A4/5 isozymes with 2.5-, 1.9-, 1.5- and 1.5-fold increase in caffeine, omeprazole, dextromethorphan, and midazolam exposure, respectively <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>, <linkHtml href="#S7.2">(7.2)</linkHtml>]</content>.</paragraph>
                              <paragraph>There was no significant impact of osilodrostat (30 mg twice daily for 12 days) on the exposure of oral contraceptives containing 0.03 mg estradiol and 0.15 mg levonorgestrel in healthy female subjects.</paragraph>
                           </text>
                           <effectiveTime value="20250425"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="9f33229f-6d5a-4ed6-9866-284aa84a26e6"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250425"/>
               <component>
                  <section ID="S13.1">
                     <id root="d5c835c9-f92a-41ae-8696-3b29fd637d23"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1	Carcinogenesis, Mutagenesis, and Impairment of Fertility</title>
                     <effectiveTime value="20250425"/>
                     <component>
                        <section>
                           <id root="7b8bc581-551a-4a1e-80ce-87200fb763af"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Carcinogenicity studies were conducted in Wistar Han rats and CD1 mice. Hepatocellular adenomas and carcinomas occurred in male rats at â¥ 10 mg/kg and in females at 30 mg/kg (18- and 65-times the 30 mg twice daily maximum clinical dose, by AUC, respectively). Thyroid follicular adenoma/carcinoma was also observed in male rats at 30 mg/kg. Hepatocellular adenomas and carcinomas occurred in male mice at â¥ 10 mg kg (6 times the maximum clinical dose, by AUC) but not in female mice at any dose â¤ 30 mg/kg (31 times the maximum clinical dose, by AUC). These findings are likely rodent specific and considered not relevant to humans. Genetic profiling studies support activation of hepatic constitutive androstane receptors as the likely tumorigenic mechanism in rodents and is not a significant concern for human risk at clinical exposure to osilodrostat.</paragraph>
                           </text>
                           <effectiveTime value="20250425"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="bfdbf911-632c-45a4-bd19-6bc95c244bd0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Genotoxicity</content>
                              </paragraph>
                              <paragraph>Genotoxicity assays conducted <content styleCode="italics">in vitro</content> in bacterial systems and <content styleCode="italics">in vitro</content> and <content styleCode="italics">in vivo</content> in mammalian systems with and without metabolic activation indicate that there is no genotoxic risk in humans with osilodrostat. </paragraph>
                           </text>
                           <effectiveTime value="20250425"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="a51c5a5b-b475-4faa-adce-7b797ee18805"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>In a fertility and early embryonic-development study in Wistar Han rats, doses of 50 mg/kg (118 times the 30 mg twice daily maximum clinical dose, by AUC) resulted in changes to estrous cyclicity and impaired female fertility and embryo viability. No effect on reproductive performance in females was observed at 5 mg/kg (8 times the maximum clinical dose). Fertility and reproductive performance were not affected in male rats up to 50 mg/kg (77 times the maximum clinical dose, by AUC).</paragraph>
                           </text>
                           <effectiveTime value="20250425"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="00b68cec-5140-4c68-a172-7955fc1c4af4"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The safety and efficacy of ISTURISA was assessed in a 48-week, multicenter study (called the Core Period) that consisted of four study periods as follows:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Period 1: 12-week, open-label, dose titration period</item>
                     <item>Period 2: 12-week, open-label, maintenance treatment period</item>
                     <item>Period 3: 8-week, double-blind, placebo-controlled, randomized withdrawal treatment period which provided the data for the primary efficacy endpoint</item>
                     <item>Period 4: open-label treatment period of 14 to 24 weeks duration</item>
                  </list>
                  <paragraph>The trial enrolled Cushing's disease patients with persistent or recurrent disease despite pituitary surgery or de novo patients for whom surgery was not indicated or who had refused surgery. The mean age at enrollment was 41 years; 77% of patients were female. There were 65% Caucasian, 28% Asian, 3% black, and 4% other race. Overall, 96% patients had received previous treatments for Cushing's disease prior to entering the study, of which 88% had undergone surgery. Persistence or recurrence of Cushing's disease was evidenced by the mean of three 24-hour UFC (mUFC) &gt; 1.5Ã upper limit of normal (ULN). The mUFC (SD) at baseline was 1006 nmol/24 hr (1589), which corresponds to approximately 7 Ã ULN. The median mUFC at baseline was 476 nmol/24 hr, which corresponds to approximately 3.5 Ã ULN.</paragraph>
               </text>
               <effectiveTime value="20250425"/>
               <component>
                  <section>
                     <id root="958ff306-f431-4dad-8c08-0cef7fa9e24d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Period 1 (Week 1 to 12)</content>
                        </paragraph>
                        <paragraph>137 patients received a starting dose of 2 mg ISTURISA orally twice daily that could be titrated up to a maximum of 30 mg twice daily at no greater than 2-week intervals to achieve a mUFC within the normal range. Individual dose adjustments were based on mUFC. The dose was increased if mUFC was above ULN and was reduced if mUFC was below the lower limit of normal (LLN), or if the patient had symptoms consistent with hypocortisolism and mUFC was in the lower part of the normal range.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="7e52c044-5e38-4e20-9380-1e9b6e68f5ba"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Period 2 (Week 13 to 24)</content>
                        </paragraph>
                        <paragraph>130 patients entered Period 2. The daily dose for patients that achieved a mUFC within the normal range in Period 1 was maintained during Period 2. Patients who did not require further dose increase, tolerated the drug, and had a mUFC â¤ ULN at Week 24 (end of Period 2) were to be considered responders and eligible to enter the Randomization Withdrawal phase (Period 3). Patients whose mUFC became elevated during Period 2 could have their dose increased further, if tolerated, up to 30 mg twice daily. These patients were considered non-responders and did not enter Period 3 but continued open-label treatment together with the patients who did not achieve normal mUFC at Week 12 and were followed for long-term safety and response to treatment.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2e0040cb-44b5-4755-b496-a395d2393f78"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Period 3 (Week 26 to 34)</content>
                        </paragraph>
                        <paragraph>At Week 26, 71 patients were considered responders and were randomized 1:1 to continue receiving ISTURISA (n = 36) or to switch to placebo (n = 35) for 8 weeks. Patients were stratified at randomization according to dose received at Week 24 (â¤ 5 mg twice daily vs 5 mg twice daily) and history of pituitary irradiation (yes/no).</paragraph>
                        <paragraph>Patients were to remain on their assigned treatment and dose throughout Period 3 if mUFC were within the normal range. Blinded dose reduction or temporary discontinuation for safety or tolerability reasons were permitted. Dose increases were not permitted during Period 3. Patients with mUFC increase &gt; 1.5 Ã ULN or who required a dose increase were considered non-responders and discontinued from Period 3 but allowed to receive open-label treatment during Period 4.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="48849759-6afc-420e-a084-05c635c74776"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Period 4 (Week 26 or 34 to 48)</content>
                        </paragraph>
                        <paragraph>This period included patients who were not eligible for randomization (n = 47) at Week 26, patients who were considered non-responders during Period 3 (n = 29), and patients who were considered responders during Period 3 (n = 41). Open-label treatment with ISTURISA continued in these patients until Week 48 when patients who maintained clinical benefit on ISTURISA, as judged by the Investigator, had an option to enter an extension period.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="e7a19810-0987-4c0c-ab71-0699da40cb88"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Efficacy Assessment</content>
                        </paragraph>
                        <paragraph>The primary efficacy endpoint of the study was to compare the percentage of complete responders at the end of the 8-week randomized withdrawal period (Period 3) between patients randomized to continue ISTURISA versus the patients switched to placebo. A complete responder for the primary endpoint was defined as a patient who had mUFC â¤ ULN based on central laboratory result at the end of Period 3 (Week 34), and who neither discontinued randomized treatment or the study nor had any dose increase above their Week 26 dose.</paragraph>
                        <paragraph>The key secondary endpoint was to assess the complete responder rate at the end of Period 2 (Week 24). A complete responder for the key secondary endpoint was defined as a patient with mUFC â¤ ULN at Week 24 who did not require an increase in dose above the level established at the end of Period 1 (Week 12). Patients who were missing mUFC assessment at Week 24 were counted as non-responders for the key secondary endpoint.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                     <component>
                        <section>
                           <id root="e6c57b6c-7828-4687-bebf-2b6cd37190bc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline italics">Results</content>
                              </paragraph>
                              <paragraph>At the end of Period 3, the percentage of complete responders for the primary endpoint was 86% and 29% in the ISTURISA and placebo groups, respectively (Table 3). The difference in percentage of complete responders between ISTURISA and placebo groups was 57%, with 95% two-sided CI of (38, 76). The 95% CI were not presented by individual strata due to the small sample sizes of some of these strata.</paragraph>
                              <table width="80%">
                                 <caption>Table 3: Percentage of Cushing's Disease Patients with Normal mUFC at End of Period 3 (8-week randomized withdrawal period)</caption>
                                 <col width="30%" align="left" valign="middle"/>
                                 <col width="20%" align="left" valign="middle"/>
                                 <col width="20%" align="left" valign="middle"/>
                                 <col width="30%" align="left" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Primary Endpoint</th>
                                       <th styleCode="Rrule">ISTURISA <br/> (N = 36) <br/> n (%)</th>
                                       <th styleCode="Rrule">Placebo <br/> (N = 34) <br/> n (%)</th>
                                       <th styleCode="Rrule">Complete Responder Rate Difference <br/> (Differences in Percentages)</th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td colspan="4">Abbreviation: CI, Confidence Interval.</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Complete responder rate at the end of the 8-week randomized withdrawal period (Week 34)</td>
                                       <td styleCode="Rrule">31 (86)</td>
                                       <td styleCode="Rrule">10 (29)</td>
                                       <td styleCode="Rrule">osilodrostat vs placebo <br/> 57 (38, 76)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">(95% CI)</td>
                                       <td styleCode="Rrule">(71, 95)</td>
                                       <td styleCode="Rrule">(15, 47)</td>
                                       <td styleCode="Rrule">2-sided p-value &lt; 0.001</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>The key secondary endpoint, complete responder rate after 24 weeks of treatment with ISTURISA was achieved by 72/137 patients (52.6%) with 95% two-sided CI of (43.9, 61.1). The lower bound of this 95% CI exceeded 30%, the pre-specified threshold for statistical significance and minimum threshold for clinical benefit.</paragraph>
                              <paragraph>At Week 48, 91/137 patients (66%) had normal mUFC levels.</paragraph>
                              <paragraph>Variable decreases from baseline for blood pressure, glucose parameters, weight and weight circumference were observed at Week 48. However, because the study allowed initiation of anti-hypertensive and anti-diabetic medications and dose increases in patients already receiving such medications and the absence of a control group, the individual contribution of ISTURISA or of anti-hypertensive and anti-diabetic medication adjustments cannot be clearly established.</paragraph>
                           </text>
                           <effectiveTime value="20250425"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="19974ec0-2fbe-484c-9157-4380f876e5c2"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20250425"/>
               <component>
                  <section>
                     <id root="d5342e8d-cc8f-4227-a459-42ef8548e45a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">How Supplied</content>
                        </paragraph>
                        <paragraph>ISTURISA (osilodrostat) tablets are supplied as follows:</paragraph>
                        <table width="80%">
                           <col width="20%" align="left" valign="top"/>
                           <col width="30%" align="left" valign="bottom"/>
                           <col width="30%" align="left" valign="middle"/>
                           <col width="20%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" valign="bottom">Tablet Strength</th>
                                 <th styleCode="Rrule">Description</th>
                                 <th styleCode="Rrule" valign="bottom">Package Configuration</th>
                                 <th styleCode="Rrule" valign="bottom">NDC No. </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="botrule">
                                 <td styleCode="Lrule Rrule">1 mg</td>
                                 <td styleCode="Rrule">Pale yellow, unscored, round, biconvex with beveled edge tablet, debossed "1" on one side.</td>
                                 <td styleCode="Rrule" rowspan="2">Each carton contains 3 blister packs. Each blister pack contains 20 tablets.</td>
                                 <td styleCode="Rrule">55292-330-60</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">5 mg</td>
                                 <td styleCode="Rrule">Yellow, unscored, round, biconvex with beveled edge tablet, debossed "5" on one side.</td>
                                 <td styleCode="Rrule">55292-331-60</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="e2a51d84-689f-4e20-98bb-749a735c38d1"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage and Handling</content>
                        </paragraph>
                        <paragraph>Store at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C); excursions permitted 15Â°C to 30Â°C (59Â°F to 86Â°F); protect from moisture.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="005b9305-f5db-4921-8231-03920c49d0d5"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise patients to read the FDA-approved patient labeling (Patient Information).</paragraph>
               </text>
               <effectiveTime value="20250425"/>
               <component>
                  <section>
                     <id root="bf3b6b48-5ccb-4be5-8597-1a7e98241c71"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Monitoring</content>
                        </paragraph>
                        <paragraph>Instruct patients on the importance of laboratory monitoring and adhering to their return visit schedule <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2</linkHtml>, <linkHtml href="#S2.3">2.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="88178be1-f9eb-4789-9f5f-e40c533a2ab9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypocortisolism</content>
                        </paragraph>
                        <paragraph>Advise patients that ISTURISA is associated with hypocortisolism-related events. Advise patients to report symptoms of hypercortisolism to their healthcare provider <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="1b91da4b-830c-4474-9778-15bbbb75bb4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">QT Prolongation</content>
                        </paragraph>
                        <paragraph>Advise patients of the signs and symptoms of QT prolongation. Advise patients to contact their healthcare provider immediately for signs or symptoms of QT prolongation.</paragraph>
                        <paragraph>Advise patients that an ECG will be taken before treatment and periodically thereafter. Advise patients with cardiac disease and risk factors for QT prolongation that adjustments in cardiac medications may be made and electrolyte disturbances may require correction <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="8cbe11f1-5f50-4aad-bfe9-4873f584fad5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adrenal Hormone Precursors/Androgens</content>
                        </paragraph>
                        <paragraph>Advise patients that elevation of adrenal hormone precursors may occur and lead to low potassium levels, worsening of hypertension, and edema. Advise patients to report the occurrence of these symptoms to their healthcare provider.</paragraph>
                        <paragraph>Advise patients that elevations of androgens may occur and may lead to hirsutism, hypertrichosis, and acne (in females). Advise patients to report the occurrence of these symptoms to their healthcare provider <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="80fd6582-aaae-4fcc-be7c-18e2dffceda9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Advise females not to breastfeed during treatment with ISTURISA and for at least one week after treatment <content styleCode="italics">[see <linkHtml href="#S8.2">Use in Specific Populations (8.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250425"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="39165a9e-b366-43cf-b420-fbf84fa3823c"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured for: <br/> Recordati Rare Diseases Inc. <br/> Bridgewater, NJ 08807 USA</paragraph>
                  <paragraph>Â© Recordati</paragraph>
               </text>
               <effectiveTime value="20250425"/>
            </section>
         </component>
         <component>
            <section>
               <id root="62dec6af-3712-4138-a536-41e1fa91da49"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <col width="50%" align="left" valign="middle"/>
                     <col width="50%" align="left" valign="middle"/>
                     <thead>
                        <tr>
                           <th colspan="2" styleCode="Lrule Rrule" align="center">PATIENT INFORMATION <br/> ISTURISA<sup>Â®</sup> (is tur ee' sah) <br/> (osilodrostat) tablets</th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td>This Patient Information has been approved by the U.S. Food and Drug Administration.</td>
                           <td align="right">Revised: 04/2025Â Â Â Â Â Â Â Â Â Â Â Â Â Â </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold" ID="whatisthemost">What is the most important information I should know about ISTURISA? <br/> ISTURISA can cause serious side effects, including:</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">Low cortisol levels in your blood (hypocortisolism).</content>
                                 </item>
                              </list>									 									Tell your healthcare provider right away if you experience <content styleCode="bold">more than one</content> of the following symptoms, as these may be symptoms of very low cortisol level, known as adrenal insufficiency: 									</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule">
                              <list listType="unordered" styleCode="disc">
                                 <item>nausea</item>
                                 <item>vomiting</item>
                                 <item>tiredness (fatigue)</item>
                                 <item>low blood pressure</item>
                                 <item>problems with body salt (electrolyte) levels in your blood</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="disc">
                                 <item>stomach (abdominal) pain</item>
                                 <item>loss of appetite</item>
                                 <item>dizziness</item>
                                 <item>low blood sugar</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="2">If you get symptoms of hypocortisolism while taking ISTURISA, your healthcare provider may change your dose or ask you to stop taking it. <br/>
                              <content styleCode="bold">Heart problem or a heart rhythm problem, such as an irregular heartbeat which could be a sign of a heart problem called QT prolongation. Call your healthcare provider right away if you have irregular heartbeats. <br/> See <linkHtml href="#possiblesideeffects">"What are the possible side effects of ISTURISA?"</linkHtml> for more information about side effects.</content>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">What is ISTURISA?</content>
                              <br/> ISTURISA is a prescription medicine that is used to treat elevated levels of cortisol in the blood (endogenous hypercortisolemia) in adults with Cushing's syndrome: 									<list listType="unordered" styleCode="disc">
                                 <item>who cannot have surgery, <content styleCode="bold">or</content>
                                 </item>
                                 <item>who have had surgery, but the surgery did not cure their Cushing's syndrome</item>
                              </list>									It is not known if ISTURISA is safe and effective in children.</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">Before you take ISTURISA, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>have or had heart problems, such as an irregular heartbeat, including a condition called prolonged QT syndrome (QT internal prolongation). Your healthcare provider will check the electrical signal of your heart (called an electrocardiogram) before you start taking ISTURISA, 1 week after starting ISTURISA, and as needed after that.</item>
                                 <item>have a history of low levels of potassium or magnesium in your blood.</item>
                                 <item>have liver problems.</item>
                                 <item>are pregnant or plan to become pregnant. It is not known if ISTURISA will harm your unborn baby. There are risks to the mother and unborn baby associated with active Cushing's syndrome during pregnancy.</item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if ISTURISA passes into your breast milk. You <content styleCode="bold">should not</content> breastfeed if you take ISTURISA and for 1 week after stopping treatment.</item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take, including</content> prescription medicines, over-the-counter medicines, vitamins, and herbal supplements. <br/> Especially tell your healthcare provider if you take medicines used to treat certain heart problems. Ask your healthcare provider if you are not sure whether your medicine is used to treat heart problems.</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">How should I take ISTURISA?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Take ISTURISA exactly as your healthcare provider tells you. Your healthcare provider will tell you exactly how many tablets of ISTURISA to take. Do not change your dose or stop taking ISTURISA unless your healthcare provider tells you to.</item>
                                 <item>Start ISTURISA by taking 2 mg two times a day by mouth or as directed by your healthcare provider.</item>
                                 <item>After you have started treatment, your healthcare provider may change your dose, depending on how you respond to the treatment with ISTURISA.</item>
                                 <item>Take ISTURISA with or without food.</item>
                                 <item>If you miss a dose of ISTURISA, take the next dose at your regularly scheduled time.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold" ID="possiblesideeffects">What are the possible side effects of ISTURISA?</content>
                              <br/>
                              <content styleCode="bold">ISTURISA may cause serious side effects, including:</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">See <linkHtml href="#whatisthemost">"What is the most important information I should know about ISTURISA?"</linkHtml>
                                    </content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Increase in other adrenal hormone levels.</content> Your other adrenal hormones may increase when you take ISTURISA. Your healthcare provider may monitor you for the symptoms associated with these hormonal changes while you are taking ISTURISA: 										<list listType="unordered" styleCode="disc">
                                       <item>
                                          <content styleCode="bold">Low potassium (hypokalemia)</content>.</item>
                                       <item>
                                          <content styleCode="bold">High blood pressure (hypertension)</content>.</item>
                                       <item>
                                          <content styleCode="bold">Swelling (edema)</content> in the legs, ankles or other signs of fluid retention.</item>
                                       <item>
                                          <content styleCode="bold">Excessive facial or body hair growth (hirsutism)</content>.</item>
                                       <item>
                                          <content styleCode="bold">Acne</content> (in women).</item>
                                    </list>
                                 </item>
                              </list>									Call your healthcare provider if you have any of these side effects.<br/>
                              <content styleCode="bold">The most common side effects of ISTURISA include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule">
                              <list listType="unordered" styleCode="disc">
                                 <item>very low cortisol levels (adrenal insufficiency)</item>
                                 <item>tiredness (fatigue)</item>
                                 <item>nausea</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="disc">
                                 <item>headache</item>
                                 <item>swelling of the legs, ankles or other signs of fluid retention (edema)</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="2">These are not all of the possible side effects of ISTURISA. <br/> Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">How should I store ISTURISA?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Store ISTURISA at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C).</item>
                                 <item>Keep ISTURISA dry.</item>
                              </list>
                              <content styleCode="bold">Keep ISTURISA and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">General information about the safe and effective use of ISTURISA.</content>
                              <br/> Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ISTURISA for a condition for which it was not prescribed. Do not give ISTURISA to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for more information about ISTURISA that is written for healthcare professionals.</td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="2">
                              <content styleCode="bold">What are the ingredients in ISTURISA?</content>
                              <br/>
                              <content styleCode="bold">Active ingredient:</content> osilodrostat phosphate <br/>
                              <content styleCode="bold">Inactive ingredients:</content> colloidal silicon dioxide, croscarmellose sodium, mannitol, microcrystalline cellulose, and magnesium stearate. Tablet film-coating: hypromellose, titanium dioxide, ferric oxide (yellow), ferric oxide (red) (1 mg only), polyethylene glycol 4000, and talc. </td>
                        </tr>
                        <tr styleCode="botrule">
                           <td styleCode="Lrule Rrule" colspan="2">For more information, go to www.ISTURISA.com or call 1-888-575-8344. <br/> Manufactured for: Recordati Rare Diseases Inc., Bridgewater, NJ 08807 USA <br/> Â© Recordati</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250425"/>
            </section>
         </component>
         <component>
            <section>
               <id root="e9941ecb-1629-4b12-864e-03bc39c33033"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 1 mg Blister Pack Carton - 330</title>
               <text>
                  <paragraph>NDC 55292-330-60</paragraph>
                  <paragraph>Isturisa<sup>Â®</sup> 1 mg<br/> (osilodrostat)<br/> tablets</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>Each tablet contains 1 mg osilodrostat (as osilodrostat phosphate).</paragraph>
                  <paragraph>60 film-coated tablets</paragraph>
                  <paragraph>RECORDATI<br/> RARE DISEASES</paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
               </text>
               <effectiveTime value="20250425"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>PRINCIPAL DISPLAY PANEL - 1 mg Blister Pack Carton - 330</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="isturisa-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="b958b7ee-33ff-469e-b3b4-5013f80d0212"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 5 mg Blister Pack Carton - 331</title>
               <text>
                  <paragraph>NDC 55292-331-60</paragraph>
                  <paragraph>Isturisa<sup>Â®</sup> 5 mg<br/> (osilodrostat)<br/> tablets</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>Each tablet contains 5 mg osilodrostat (as osilodrostat phosphate).</paragraph>
                  <paragraph>60 film-coated tablets</paragraph>
                  <paragraph>RECORDATI<br/> RARE DISEASES</paragraph>
                  <renderMultiMedia referencedObject="MM5"/>
               </text>
               <effectiveTime value="20250425"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>PRINCIPAL DISPLAY PANEL - 5 mg Blister Pack Carton - 331</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="isturisa-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="d50a079c-f4ff-4307-97af-a68ce0ad7941"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 1 mg Blister Pack Carton</title>
               <text>
                  <paragraph>NDC 55292-320-60</paragraph>
                  <paragraph>Isturisa<sup>Â®</sup>
                     <br/>(osilodrostat)<br/>tablets</paragraph>
                  <paragraph>1 mg</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>Each tablet contains 1 mg osilodrostat (as osilodrostat phosphate).</paragraph>
                  <paragraph>60 film-coated tablets</paragraph>
                  <paragraph>RECORDATI<br/>RARE DISEASES</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20250425"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>PRINCIPAL DISPLAY PANEL - 1 mg Blister Pack Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="isturisa-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="535b24ab-ce52-4c30-88d1-d6937412e04e"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 5 mg Blister Pack Carton</title>
               <text>
                  <paragraph>NDC 55292-321-60</paragraph>
                  <paragraph>Isturisa<sup>Â®</sup>
                     <br/>(osilodrostat)<br/>tablets</paragraph>
                  <paragraph>5 mg</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>Each tablet contains 5 mg osilodrostat (as osilodrostat phosphate).</paragraph>
                  <paragraph>60 film-coated tablets</paragraph>
                  <paragraph>RECORDATI<br/>RARE DISEASES</paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20250425"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>PRINCIPAL DISPLAY PANEL - 5 mg Blister Pack Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="isturisa-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_84a04e6b-31d8-4fc5-b27f-e31378146c41">
               <id root="f9b1d5d0-bed7-4d0c-a665-4feadde6c1e0"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL </title>
               <text>
                  <renderMultiMedia ID="id-1551604559" referencedObject="ID_5af9bc28-46c4-422b-af06-81d7dadefa2b"/>
               </text>
               <effectiveTime value="20250425"/>
               <component>
                  <observationMedia ID="ID_5af9bc28-46c4-422b-af06-81d7dadefa2b">
                     <text>Isturisa (osilodrostat) tablets, 10 mg label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="isturisa-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>